Dyne Therapeutics, Inc. (DYN)

NASDAQ: DYN · USD

$17.0

+0.02 (+0.1%)· Recorded snapshot

Market cap	3.2B
Net income (ttm)	-519.4M
EPS (ttm)	-$3.35
Shares out	186.7M
Volume	1,812,284
Beta	1.12

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Net income (ttm): -519.4M
EPS (ttm): -$3.35
Market cap: 3.2B

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	Aanhouden

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 n/aP50 n/aP75 n/a

Trailing P/En/a

P25 n/aP50 n/aP75 n/a

ROE-81.6

P25 n/aP50 n/aP75 n/a

ROIC-41.2

P25 n/aP50 n/aP75 n/a

Benchmarks · 1M

All DYN indicators

Market & fundamental data

Available fields

184

Groups with data

Currency

USD

Showing 184 of 184 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001818794
Company name	Dyne Therapeutics, Inc.
Country	United States
Country code	US
CUSIP number	26818M108
Earnings date	2026-11-09
Earnings time	bmo
Employees	289
Employees change	83
Employees growth	40.29%
Enterprise value	$2.5B
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	1984
In index	RUSSELL2000
Industry	Biotechnology
IPO date	2020-09-17
Is primary listing	Yes
Is SPAC	No
ISIN number	US26818M1080
Last 10-K release date	2018-02-22
Last earnings date	2026-07-29
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$3.2B
Market cap category	Mid-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$16.96
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	DYN
U.S. state	Massachusetts
Website	https://www.dyne-tx.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-19.74%
FCF / EV yield	-19.98%
FCF yield	-15.78%
Forward EV/Sales	236.81x
Forward P/S	299.85x
P/B ratio	4x
Price / tangible book value	4.51x
Sector forward P/E	23.56x
Sector P/E	50.08x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Profit per employee	$-1.8M
ROA	-38.96%
ROA (5Y)	-39.77%
ROCE	-58.62%
ROE	-81.57%
ROE (5Y)	-75.45%
ROIC	-41.23%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth years	0
Net income growth years	0
Revenue growth years	0

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
Capital expenditures	$-21.4M
Depreciation and amortization	$2.2M
EBIT	$-537M
EBITDA	$-534.8M
EPS	$-3.35
FCF per share	$-2.67
Financing cash flow	$713.5M
Free cash flow	$-499.2M
Free cash flow minus SBC	$-549.6M
Investing cash flow	$-44.2M
Net borrowing	$113M
Net cash flow	$191.5M
Net income	$-519.4M
Operating cash flow minus SBC	$-528.2M
Operating income	$-537M
Stock-based compensation	$50.4M

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Book value per share	$4.24
Debt / equity	0.33
Interest coverage	-36.05
Long-term assets	$56.1M
Long-term liabilities	$213.8M
Net cash (debt)	$665.1M
Net cash / market cap	21.03%
Net cash growth	18.17%
Net debt / equity	-0.95
Piotroski F-Score	1
Property, plant and equipment	$44.8M
Shareholders' equity	$702.2M
Tangible book value	$702.2M
Tangible book value per share	$4.24
Total assets	$994M
Total cash	$898.5M
Total debt	$233.4M
Total liabilities	$291.9M
WACC	10.04%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current assets	$937.9M
Current liabilities	$78M
Current ratio	12.02
Net working capital	$-19.1M
Quick ratio	11.51
Working capital	$859.9M

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-45.37%
Dividend yield	0%
Shareholder yield	-45.37%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
150-day SMA	$20.06
1D price change	0.12%
1M price change	5.8%
1M total return	5.8%
1W price change	5.54%
1W total return	5.54%
1Y price change	-29.83%
1Y return CAGR	-29.85%
1Y total return	-29.83%
20-day SMA	$15.76
200-day SMA	$19.31
3M price change	-33.83%
3M total return	-33.83%
3Y price change	156.19%
3Y return CAGR	36.82%
3Y total return	156.19%
50-day SMA	$18.91
50-day SMA vs 200-day SMA	50under200
52-week high	$27.31
52-week high date	2026-08-12
52-week low	$14.00
52-week low date	2026-03-02
5Y price change	18.77%
5Y return CAGR	3.5%
5Y total return	18.77%
6M price change	-5.99%
6M total return	-5.99%
All-time high	$47.45
All-time high date	2024-08-20
All-time low	$4.30
All-time low date	2022-06-02
Average true range (ATR)	$0.92
Average volume	3M
Beta (1Y)	1.67
Beta (2Y)	1.68
Beta (5Y)	1.12
Change from 52-week high	-37.89%
Change from 52-week low	21.14%
Change from all-time high	-64.26%
Change from all-time low	294.42%
Change from open	4.05%
Day's gap	-3.78%
Dollar volume	$30.7M
High price	$17.10
Low price	$16.11
Monthly RSI	47.18
Open price	$16.30
Position in 52-week range	85.86%
Premarket change	-4.07%
Premarket close	$16.94
Premarket price	$16.25
Premarket volume	77.3K
Previous close	$16.94
Price vs 150-day SMA	-15.46%
Price vs 20-day SMA	7.59%
Price vs 200-day SMA	-12.18%
Price vs 50-day SMA	-10.32%
Relative volume	0.6
Return from IPO open	-25.01%
Return from IPO price	-10.84%
RSI	52.35
Sharpe ratio	-0.27
Sharpe ratio (3Y)	0.74
Sharpe ratio (5Y)	0.39
Sortino ratio	-0.29
Sortino ratio (3Y)	1.22
Sortino ratio (5Y)	0.67
Volume	1.8M
Weekly RSI	44.5
YTD price change	-13.29%
YTD total return	-13.29%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	186.2M
Float percentage	99.73%
Shares change (QoQ)	0.25%
Shares change (YoY)	45.37%
Shares held by insiders	0.27%
Shares held by institutions	100.86%
Shares outstanding	186.7M
Short % of float	13.95%
Short % of shares	13.91%
Short ratio	7.3 days

Deeper analysis on DYN

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this DYN report

Is a complete DYN research report available?

No complete published report is available for Dyne Therapeutics, Inc. (DYN) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Dyne Therapeutics, Inc. (DYN)

Price

Financial snapshot

Fair-value bridge

Latest news · DYN

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All DYN indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on DYN

Frequently asked questions